Titel

Merkliste
1 Ergebnisse

Phase 1 study of the pan-HER inhibitor dacomitinib plus the..:

van Geel, Robin M.J.M ; van Brummelen, Emilie M.J ; Eskens, Ferry A.L.M...
van Geel , R M J M , van Brummelen , E M J , Eskens , F A L M , Huijberts , S C F A , de Vos , F Y F L , Lolkema , M P J K , Devriese , L A , Opdam , F L , Marchetti , S , Steeghs , N , Monkhorst , K , Thijssen , B , Rosing , H , Huitema , A D R , Beijnen , J H , Bernards , R & Schellens , J H M 2020 , ' Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer ' , British Journal of Cancer , vol. 122 , no. 8 , pp. 1166-1174 . https://doi.org/10.1038/s41416-020-0776-z. , 2020

Link: https://pure.eur.nl/en/publications/2b3fcc01-8b9a-4ad5..

RT Journal
T1 <Title>Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer</Title>

UL https://suche.suub.uni-bremen.de/peid=base-fturottercrispub:oai:pure.eur.nl:publications_2b3fcc01-8b9a-4ad5-b332-b72ee2392684&Exemplar=1&LAN=DE
				
A1 van Geel, Robin M.J.M
A1 van Brummelen, Emilie M.J
A1 Eskens, Ferry A.L.M
A1 Huijberts, Sanne C.F.A
A1 de Vos, Filip Y.F.L
A1 Lolkema, Martijn P.J.K
A1 Devriese, Lot A
A1 Opdam, Frans L
A1 Marchetti, Serena
A1 Steeghs, Neeltje
A1 Monkhorst, Kim
A1 Thijssen, Bas
A1 Rosing, Hilde
A1 Huitema, Alwin D.R
A1 Beijnen, Jos H
A1 Bernards, René
A1 Schellens, Jan H.M
YR 2020
K1 /dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being
K1 SDG 3 - Good Health and Well-being
JF van Geel , R M J M , van Brummelen , E M J , Eskens , F A L M , Huijberts , S C F A , de Vos , F Y F L , Lolkema , M P J K , Devriese , L A , Opdam , F L , Marchetti , S , Steeghs , N , Monkhorst , K , Thijssen , B , Rosing , H , Huitema , A D R , Beijnen , J H , Bernards , R & Schellens , J H M 2020 , ' Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer ' , British Journal of Cancer , vol. 122 , no. 8 , pp. 1166-1174 . https://doi.org/10.1038/s41416-020-0776-z
LK http://dx.doi.org/https://pure.eur.nl/en/publications/2b3fcc01-8b9a-4ad5-b332-b72ee2392684
DO https://pure.eur.nl/en/publications/2b3fcc01-8b9a-4ad5-b332-b72ee2392684
SF ELIB - SuUB Bremen

Export

RefWorks (nur Desktop-Version!)
Flow (Zuerst in Flow einloggen, dann importieren)